Clinical Trial

Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 11, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of relapsed and/or refractory AML
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-03-23; most recent amendment 2025-09-04.
Status change: Not Yet Recruiting → Recruiting 2022-08-01
Trial Details
NCT Number NCT05305859
Lead Sponsor The First Affiliated Hospital of Xiamen University
Collaborators: Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou manicipal hospital of Fujian Province, Jieyang People's Hospital, Dongguan People's Hospital, Huizhou Municipal Central Hospital
Conditions Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
Enrollment 30 participants
Start Date 2022-01-12
Primary Completion 2026-01-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-11